PUBLIC SUMMARY DOCUMENT
Product: Eakin Protect Wipes
Applicant: Omnigon Pty Ltd
Date of SPAP Meeting: 17 & 18 August 2015
1. Proposed Listing on the Stoma Appliance Scheme
The applicant, Omnigon, sought listing of Eakin Protect Wipes in subgroup 9(k) of the Stoma
Appliance Scheme (SAS) Schedule. The product was proposed for listing at the unit price of
$1.065 per wipe, with a maximum monthly quantity of 30 units.
2. Comparator
The applicant nominated WBF Barrier Film (SAS code 9970R) from its own range which is
currently listed in subgroup 9(k) as the comparator. This product is currently listed at a unit
price of $1.065, with a maximum monthly quantity of 30 units.
3. Background
This was the Stoma Product Assessment Panel (SPAP)’s first consideration of this product.
4. Clinical Place for the Product
The proposed product provides an alternative for users requiring barrier wipes for application
to the peristomal skin before an ostomy appliance.
5.
SPAP Comment
Clinical Analysis
The Panel noted that the proposed product is a sting free (no alcohol) silicone based,
individually wrapped wipe. It appears to be ‘no worse than’ current wipes in subgroup 9(k).
Economic Analysis
In May 2015 the panel recommended that the benchmark price of ‘non-sting’ wipes listed in
subgroup 9(k) should be reduced to $0.29 per unit. This recommendation was accepted. A
review of products currently listed at $1.065 per unit will be undertaken in 2016 and the
prices reduced unless satisfactory evidence is provided to justify a price premium.
Any new products including the proposed product will be listed at the new benchmark price
of $0.29 per unit.
Financial Analysis
As a result of listing the product at a lower price compared with the nominated comparator in
subgroup 9(k), listing the product would result in a cost reduction to Government.
6. SPAP Recommendation
The SPAP recommended that the Eakin Protect Wipes be listed in subgroup 9(k) on the SAS
Schedule, at a unit price of $0.29 per wipe, with a maximum monthly quantity of 30 units.
If the applicant considers that the proposed product should be listed on the SAS Schedule at
more than the new price of $0.29 per unit the applicant will be required to:
OG#22
 Submit an application for the proposed product with a justification for seeking a price
premium by 31 January 2016 to be considered at a Stoma Product Assessment Panel
meeting in 2016;
 Provide a full description of the proposed product’s additional features, and
 Provide evidence of the product superiority.
The Panel also noted that all recommendations for products to be listed in Group 9 of the
SAS Schedule may be subject to change as a result of the outcomes from the Group 9
Review.
7. Context for Decision
The SPAP helps decide whether stoma products should be subsidised and, if so, the
conditions of their subsidisation in Australia. It considers submissions in this context. An
SPAP decision not to recommend listing or changes to a listing does not represent a final
SPAP view about the merits of a particular stoma product. A company can resubmit to the
SPAP following a decision not to recommend listing or changes to a listing. The SPAP is an
advisory committee and as such its recommendations are non-binding on Government. All
SPAP recommendations are subject to Cabinet/Ministerial approval.
8. Applicant’s Comment
Omnigon Pty Ltd notes SPAP’s comments and will be providing further information in
response.
OG#22